AGILENT’S CELL ANALYSIS TECHNOLOGY SUPPORTS FDA APPROVAL OF AUTOLUS CAR T THERAPY

Agilent Technologies has announced its role in the recent FDA approval of Autolus Therapeutics' CAR T therapy, AUCATZYL®, through the application of its xCELLigence Real-Time Cell Analysis (RTCA) technology. This advanced, label-free instrumentation provided continuous monitoring of cell behavior, supporting the development of a reliable potency assay for the therapy.

Agilent’s xCELLigence RTCA system helped ensure precision and accuracy in cell analysis, contributing to Autolus’ regulatory success. The platform measures electrical impedance to track cell viability and morphology in real time, offering significant advantages over traditional endpoint assays.

Executives from both companies, including Agilent’s VP Dr. Xiaobo Wang and Autolus’ CTO David Brochu, emphasized the importance of collaboration in achieving this milestone. Both firms are presenting their joint insights at the 2025 Hybrid US Bioassay Conference in Tucson.

This partnership highlights Agilent’s commitment to enabling innovation in cancer treatment and advancing real-time analytical tools that improve therapeutic development outcomes.